May 31, 2016: As Big Ten Cancer Research Consortium members work every day to defeat cancer, they are constantly aware that behind every office appointment, pathology report, and scan is the story of a survivor. In honor of National Cancer Survivors Day on June 5, we celebrate examples of our members working to improve the lives of all patients with cancer. Read More
May. 18, 2016: Big Ten cancer centers continue to make gains in cancer research and treatment. In this edition of Across the Consortium, we highlight research from our member institutions in prostate, neuroendocrine, blood, pancreatic, and other cancers; we celebrate with the University of Iowa Holden Comprehensive Cancer Center upon its receiving a Read More
Aug. 17, 2016: Barriers: to win this war against cancer, they all must come down. In this month’s edition of Across the Consortium, discover how members of the Big Ten Cancer Research Consortium are bringing down barriers. Interdisciplinary partnerships are overcoming obstacles to inoperable cancers; laser-imaging and creative tests are being leveraged to break down barriers to early diagnosis; immunotherapies are breaking down barriers to once-and-for-all remission; new predictive screening models and population-specific cancer programs are breaking down barriers to treatment of certain populations; volunteers and grants are breaking down barriers to research. All this and more, in this month’s edition of Across the Consortium! Read More
July 22, 2016: The Big Ten Cancer Research Consortium (Big Ten CRC) announces the opening of a Phase I/II clinical trial for advanced or metastatic hepatocellular carcinoma. The study, known as BTCRC-GI13-002, will be conducted in two phases. In Phase I, researchers will determine the maximum safe dose of a drug called MLN0128. In Phase II, study participants will be randomized to one of two groups. One group will receive MLN0128 and the other will receive sorafenib, the standard therapy for patients with advanced or metastatic hepatocellular carcinoma. MLN0128 is an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration to treat any disease. The Indiana University Melvin and Bren Simon... Read More
July 17, 2016: Initiative: the proactive power of progress. This key trait of leadership is exhibited by each of the Big Ten Cancer Centers. Exciting displays of initiative in the fight against cancer fill this month's edition of Across the Consortium. Engagement in national enrollment-boosting programs; patient-centered precision medicine initiatives; hosting a research summit and publishing studies in nationwide research initiatives; a nationally-recognized fundraising event; novel discoveries; and the development of game-changing diagnostic technology and immunotherapy treatments. Don't miss this action-packed edition of Across the Consortium! Read More
July 1, 2016: A new Big Ten Cancer Research Consortium study is testing whether adding palbociclib to tamoxifen might improve response rates in patients with newly diagnosed advanced hormone receptor positive, HER2 negative (HR+/HER2-) breast cancer. The single-arm phase II study, known as BTCRC-BRE15-016, is currently open for accrual at the University of Illinois Cancer Center, with additional Big Ten CRC member sites expected to open the trial in the coming months. The study is open to both pre- and post-menopausal women with HR+/HER2- advanced breast cancer who have not received prior systemic anti-cancer therapies for their advanced disease. Additional eligibility requirements must be met to enroll in the study. Read More
July 1, 2016: A conversation with Leonidas Platanias, MD, PhD, Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, which is a member of the Big Ten Cancer Research Consortium. Q: How do you think cancer research will change in the next 10 to 20 years? This is an exciting time in oncology, and we see tremendous opportunities to advance cancer prevention, diagnostics and therapeutics in ways that were unimaginable just a few years ago. Immunotherapy and genomics, two of the most compelling areas of research today, will provide... Read More
June 17, 2016: Today, cancer is the leading cause of death worldwide. In his final State of the Union address, President Barack Obama tasked Vice President Joe Biden with heading up a new national effort to end cancer as we know it. "Fifty-five years ago, President John F. Kennedy stood before a joint session of Congress and said, 'I believe we should go to the moon.'" Biden said. "This is our moonshot." As part of the White House Cancer Moonshot Task Force's "Moonshot Initiative," Vice President Biden has called on leaders across the health, academic, private industry, and philanthropic sectors to join together with patients, survivors, and advocates on June 29th for the first national summit of its kind: the 2016 Cancer... Read More
June 19, 2016: Many people excel in sports, and even amateurs get lucky now and then. But it is the relentlessly consistent accomplishment of great - and crucial - plays that makes a legend. In this month’s edition of Across the Consortium, we celebrate such plays by the unyielding Big Ten Cancer Centers. Pioneering research aims to nail important questions of our time and offer hope to countless many, from the promise of novel, natural cancer-killers to targeted cancer therapies, liquid biopsies, and bio-dynamic imaging. Meanwhile, many members institutions pull through with varsity fund-raising. Take a look Across the Consortium! Read More
May 31, 2016: As Big Ten Cancer Research Consortium members work every day to defeat cancer, they are constantly aware that behind every office appointment, pathology report, and scan is the story of a survivor. In honor of National Cancer Survivors Day on June 5, we celebrate examples of our members working to improve the lives of all patients with cancer. Read More
May. 18, 2016: Big Ten cancer centers continue to make gains in cancer research and treatment. In this edition of Across the Consortium, we highlight research from our member institutions in prostate, neuroendocrine, blood, pancreatic, and other cancers; we celebrate with the University of Iowa Holden Comprehensive Cancer Center upon its receiving a Read More
Aug. 17, 2016: Barriers: to win this war against cancer, they all must come down. In this month’s edition of Across the Consortium, discover how members of the Big Ten Cancer Research Consortium are bringing down barriers. Interdisciplinary partnerships are overcoming obstacles to inoperable cancers; laser-imaging and creative tests are being leveraged to break down barriers to early diagnosis; immunotherapies are breaking down barriers to once-and-for-all remission; new predictive screening models and population-specific cancer programs are breaking down barriers to treatment of certain populations; volunteers and grants are breaking down barriers to research. All this and more, in this month’s edition of Across the Consortium! Read More
July 22, 2016: The Big Ten Cancer Research Consortium (Big Ten CRC) announces the opening of a Phase I/II clinical trial for advanced or metastatic hepatocellular carcinoma. The study, known as BTCRC-GI13-002, will be conducted in two phases. In Phase I, researchers will determine the maximum safe dose of a drug called MLN0128. In Phase II, study participants will be randomized to one of two groups. One group will receive MLN0128 and the other will receive sorafenib, the standard therapy for patients with advanced or metastatic hepatocellular carcinoma. MLN0128 is an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration to treat any disease. The Indiana University Melvin and Bren Simon... Read More
Subscribe to the Big Ten CRC NewsletterXFacebookYouTube